ATE109467T1 - Verwendung von 4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropy idinderivaten als freie radikalfänger. - Google Patents

Verwendung von 4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropy idinderivaten als freie radikalfänger.

Info

Publication number
ATE109467T1
ATE109467T1 AT92400289T AT92400289T ATE109467T1 AT E109467 T1 ATE109467 T1 AT E109467T1 AT 92400289 T AT92400289 T AT 92400289T AT 92400289 T AT92400289 T AT 92400289T AT E109467 T1 ATE109467 T1 AT E109467T1
Authority
AT
Austria
Prior art keywords
free radical
compounds
tetrahydropyide
trifluoromethylphenyl
scraper
Prior art date
Application number
AT92400289T
Other languages
English (en)
Inventor
Michel Heaulme
Umberto Guzzi
Original Assignee
Sanofi Elf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Elf filed Critical Sanofi Elf
Application granted granted Critical
Publication of ATE109467T1 publication Critical patent/ATE109467T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
AT92400289T 1991-02-05 1992-02-05 Verwendung von 4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropy idinderivaten als freie radikalfänger. ATE109467T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9101283A FR2672213B1 (fr) 1991-02-05 1991-02-05 Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.

Publications (1)

Publication Number Publication Date
ATE109467T1 true ATE109467T1 (de) 1994-08-15

Family

ID=9409370

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92400289T ATE109467T1 (de) 1991-02-05 1992-02-05 Verwendung von 4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropy idinderivaten als freie radikalfänger.

Country Status (13)

Country Link
US (1) US5292745A (de)
EP (1) EP0498718B1 (de)
JP (1) JP3471820B2 (de)
AT (1) ATE109467T1 (de)
AU (1) AU649099B2 (de)
CA (1) CA2060616C (de)
DE (1) DE69200284T2 (de)
DK (1) DK0498718T3 (de)
ES (1) ES2061319T3 (de)
FR (1) FR2672213B1 (de)
HU (2) HU212945B (de)
IE (1) IE66593B1 (de)
MX (1) MX9200485A (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
ES2159362T3 (es) * 1995-10-26 2001-10-01 Sanofi Synthelabo Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
FR2763847B1 (fr) 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
CA2353529C (en) * 1998-12-01 2009-11-17 Alexandre T. Rotta Method for reducing free-radical induced injury
BR0212151A (pt) * 2001-08-29 2004-08-24 Alcon Inc Uso de compostos para tratar condições resultantes de dano ao nervo corneano após cirurgias de lasik e outras oculares ou traumas
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
JP2008504278A (ja) * 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
CA2589565A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
JP2008504275A (ja) * 2004-06-24 2008-02-14 インサイト・コーポレイション Ｎ−置換ピペリジンおよびその医薬としての使用
US7687665B2 (en) * 2004-06-24 2010-03-30 Incyte Corporation 2-methylprop anamides and their use as pharmaceuticals
AU2005273986A1 (en) * 2004-08-10 2006-02-23 Incyte Corporation Amido compounds and their use as pharmaceuticals

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4691019A (en) * 1981-03-11 1987-09-01 Sanofi Anorectic agent; 4-(3-trifluoromethylphenyl)-1-(2-cyanoethyl)-1,2,3,6-tetrahydropyridine
FR2501682A1 (fr) * 1981-03-11 1982-09-17 Sanofi Sa Trifluoromethylphenylpyridines a activite anorexigene, un procede de preparation et compositions pharmaceutiques en contenant
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
GB2226269B (en) * 1988-12-22 1992-11-25 Zdzislaw Bieganski Cable stripper
FR2650505B1 (fr) * 1989-08-07 1994-06-03 Midy Spa Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
DK0498718T3 (da) 1994-12-05
FR2672213B1 (fr) 1995-03-10
AU649099B2 (en) 1994-05-12
DE69200284T2 (de) 1995-03-02
DE69200284D1 (de) 1994-09-08
IE66593B1 (en) 1996-01-24
EP0498718A1 (de) 1992-08-12
IE920354A1 (en) 1992-08-12
ES2061319T3 (es) 1994-12-01
HU212945B (en) 1996-12-30
CA2060616A1 (en) 1992-08-06
HU9200335D0 (en) 1992-04-28
FR2672213A1 (fr) 1992-08-07
HU211457A9 (en) 1995-11-28
US5292745A (en) 1994-03-08
MX9200485A (es) 1992-11-01
JP3471820B2 (ja) 2003-12-02
EP0498718B1 (de) 1994-08-03
JPH04312528A (ja) 1992-11-04
AU1065592A (en) 1992-08-13
CA2060616C (en) 2004-04-06
HUT62563A (en) 1993-05-28

Similar Documents

Publication Publication Date Title
ATE109467T1 (de) Verwendung von 4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropy idinderivaten als freie radikalfänger.
DE69722027D1 (de) Kristalle von benzimidazolderivate und verfahren zu ihrer herstellung
NO20062517L (no) 2-cyanopyrrolidinkarboksamidforbindelse
NO20072116L (no) Farmasoytiske forbindelser
DE69736642D1 (de) Heterocyclische Verbindungen, ihre Herstellung und Verwendung
CA2124680A1 (en) Piperazine derivatives as 5-ht1a antagonists
ATE19513T1 (de) Neue verbindungen, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel.
ATE154937T1 (de) Steroide zur behandlung von prostatisch- hypertrophe, ihre herstellung und verwendung
DK129282A (da) Fremgangsmaade til fremstilling af indolylethylderivater
DE50011034D1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE51618T1 (de) Imidazolderivate, verfahren zu deren herstellung, deren anwendung und pharmazeutische zusammenstellungen.
DE59208426D1 (de) Guanidinalkyl-1,1-bisphosphonsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
SE8406302D0 (sv) New aminoguanidine derivatives and a process for the preparation thereof
NO972887L (no) Piperidineddiksyrederivater anvendelige som fibrinogen-antagonistmiddel
ATE24503T1 (de) Phenylpiperazin-derivate und verfahren zu deren herstellung.
DE3769563D1 (de) Neue derivate von 4,5-dihydro-oxazolen, verfahren zu ihrer herstellung und ihre verwendung.
ATE37368T1 (de) Benzothiazolon-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE27455T1 (de) Heterocyclische guanidino-phenylamidine, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
ATE261441T1 (de) Analoga von distamycin-zimtsäurederivaten, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
MA20369A1 (fr) Compositions a base de derives de la piperidine ,nouveaux derives de la piperidine et leurs procedes de preparation
ATE249459T1 (de) N-benzenesulfonyl-l-prolin-derivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
DK104388A (da) Hidtil ukendte 2-(2,3-dihydro-2-oxo-3-benzofuranyl)-eddikesyrederivater, fremgangsmaade til deres fremstilling og farmaceutiske midler indeholdende dem
ES8407475A1 (es) "un procedimiento para la preparacion de derivados de hidroxiimino y alcoxiimino de 1,4-dihidropiridina"
EP0172446A3 (de) Verwendung von Alkylendiamin-Derivaten zur Behandlung von Durchblutungsstörungen sowie Arzneimittel, die diese Verbindungen enthalten
TH8799EX (th) การใช้อนุพันธ์ของอิมิแดโซพิแรโซลเป็นสารแก้ปวดและต่อต้านการอักเสบ

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee